

Cannabics Pharma clinches clinical trial on Cannabics SR 5mg for CACS

July 5, 2018 | News

The company is awaiting for the results and expect them to further clarify an important part of their mission in integrating cannabinoid-based therapies into the world of precision medicine



An Israeli company, Cannabics Pharmaceuticals is leader in personalized cannabis medicine focused on cancer and its side effects, announced that it has concluded its clinical trial held at Rambam Medical centre.

The Oncology centre at Rambam Medical centre is recognized by the European Society for Medical Oncology (ESMO) as a designated centre of Integrated Oncology and Palliative Care.

Launched in 2016, the study involved patients with advanced Cancer and Cancer Anorexia Cachexia Syndrome (CACS) with Cannabics SR 5mg, daily for 3 months. The main endpoints that were examined were weight gain, appetite and Quality of Life (QOL).

The official results are now being evaluated by the Hospital and we expect them to be published in the next few months according to Professor Gil Bar-Sela, who ran the study and is Deputy Director of the Division of Oncology at Rambam Health Care Campus, Head of the Palliative and Supportive Oncology Unit, and Head of the service for Melanoma and Sarcoma patients.

Eyal Ballan, Chief Technical Officer of Cannabics Pharmaceuticals said: "We are very pleased to have completed this study. We are awaiting the results and expect them to further elucidate an important aspect of our mission in integrating cannabinoid-based therapies into the world of precision medicine; while at the same time focusing our efforts on bringing scientific data to support developments of cannabinoid-based therapies".